Effect of Chickpea Protein Hydrolysate Supplementation on Muscle Damage and Inflammatory Plasma Markers During a Football Tournament: A Randomized, Placebo-Controlled Crossover Trial

Summary

This randomized, placebo-controlled crossover study evaluated the safety and potential beneficial effects of a beverage containing chickpea protein hydrolysate in football players. Participants received the chickpea protein hydrolysate beverage and a matched protein-containing placebo beverage during two four-week intervention periods separated by a two-week washout period. The study assessed biochemical safety parameters, antioxidant status, inflammatory biomarkers, lipid profile, lipid peroxidation, muscle damage markers, dietary intake, and body composition.

Conditions

• Post-Exercise Recovery

Interventions

DIETARY_SUPPLEMENT

Chickpea Protein Hydrolysate Beverage

A powdered beverage containing chickpea protein hydrolysate was reconstituted in water before consumption. On training days, participants consumed a dose providing 0.2 g protein/kg body weight 2-4 hours before training and 0.3 g protein/kg body weight approximately 30 minutes after training. The intervention was administered for four weeks during the corresponding study period.

DIETARY_SUPPLEMENT

Maltodextrin Placebo Beverage

A maltodextrin-containing placebo beverage designed to resemble the chickpea protein hydrolysate beverage in appearance and taste. The placebo was administered according to the same timing schedule as the experimental beverage for four weeks during the corresponding study period.

Sponsors & Collaborators

• Universidad Pablo de Olavide

  collaborator OTHER

• CDTI (Centro para el Desarrollo Tecnologico Industrial)

  collaborator UNKNOWN

• Ministerio de Ciencia e Innovacion, Spain

  collaborator UNKNOWN

• Instituto de Biomedicina (IBiS) de Sevilla

  collaborator UNKNOWN

• Instituto de la Grasa

  lead OTHER_GOV

Principal Investigators

• Justo Javier Pedroche Jiménez, PhD · Spanish National Research Council (CSIC)

• María Soledad MS Fernández Pachón, PhD · Universidad Pablo de Olavide

• José Antonio JA González Jurado, PhD · Universidad Pablo de Olavide

• Noelia María NM Rodríguez Martín, PhD · Spanish National Research Council (CSIC)

Study Design

Allocation

RANDOMIZED

Purpose

OTHER

Masking

DOUBLE

Model

CROSSOVER

Eligibility

Min Age

16 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2022-02-14

Primary Completion

2022-05-17

Completion

2022-05-17

Countries

• Spain

Study Locations